Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Evaluation of targeted influenza vaccination strategies via population modeling.

Glasser J, Taneri D, Feng Z, Chuang JH, Tüll P, Thompson W, Mason McCauley M, Alexander J.

PLoS One. 2010 Sep 17;5(9). pii: e12777. doi: 10.1371/journal.pone.0012777.

2.

An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11.

Ng S, Wu P, Nishiura H, Ip DK, Lee ES, Cowling BJ.

BMC Infect Dis. 2011 Aug 26;11:230. doi: 10.1186/1471-2334-11-230.

3.

CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013.

Johnson NB, Hayes LD, Brown K, Hoo EC, Ethier KA; Centers for Disease Control and Prevention (CDC).

MMWR Suppl. 2014 Oct 31;63(4):3-27.

PMID:
25356673
4.

Optimal H1N1 vaccination strategies based on self-interest versus group interest.

Shim E, Meyers LA, Galvani AP.

BMC Public Health. 2011 Feb 25;11 Suppl 1:S4. doi: 10.1186/1471-2458-11-S1-S4.

5.

Age groups and spread of influenza: implications for vaccination strategy.

Hsieh YH.

BMC Infect Dis. 2010 Apr 30;10:106. doi: 10.1186/1471-2334-10-106.

6.

Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales.

Pitman RJ, White LJ, Sculpher M.

Vaccine. 2012 Feb 1;30(6):1208-24. doi: 10.1016/j.vaccine.2011.11.106. Epub 2011 Dec 13.

7.

Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season.

Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ.

Vaccine. 2015 Jan 1;33(1):246-51. doi: 10.1016/j.vaccine.2014.06.052. Epub 2014 Jun 21.

8.

Surveillance of influenza vaccination coverage--United States, 2007-08 through 2011-12 influenza seasons.

Lu PJ, Santibanez TA, Williams WW, Zhang J, Ding H, Bryan L, O'Halloran A, Greby SM, Bridges CB, Graitcer SB, Kennedy ED, Lindley MC, Ahluwalia IB, LaVail K, Pabst LJ, Harris L, Vogt T, Town M, Singleton JA; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2013 Oct 25;62(4):1-28.

9.

Vaccination against 2009 pandemic H1N1 in a population dynamical model of Vancouver, Canada: timing is everything.

Conway JM, Tuite AR, Fisman DN, Hupert N, Meza R, Davoudi B, English K, van den Driessche P, Brauer F, Ma J, Meyers LA, Smieja M, Greer A, Skowronski DM, Buckeridge DL, Kwong JC, Wu J, Moghadas SM, Coombs D, Brunham RC, Pourbohloul B.

BMC Public Health. 2011 Dec 14;11:932. doi: 10.1186/1471-2458-11-932.

10.

Prioritization of delayed vaccination for pandemic influenza.

Shim E.

Math Biosci Eng. 2011 Jan;8(1):95-112. doi: 10.3934/mbe.2011.8.95.

11.

Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.

Ryan J, Zoellner Y, Gradl B, Palache B, Medema J.

Vaccine. 2006 Nov 17;24(47-48):6812-22. Epub 2006 Aug 4.

PMID:
17034909
12.

Impact of influenza on young children and the shaping of United States influenza vaccine policy.

Terebuh P, Uyeki T, Fukuda K.

Pediatr Infect Dis J. 2003 Oct;22(10 Suppl):S231-5. Review. Erratum in: Pediatr Infect Dis J. 2004 Apr;23(4):294.

PMID:
14551482
13.

Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.

Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI.

PLoS One. 2011;6(7):e22308. doi: 10.1371/journal.pone.0022308. Epub 2011 Jul 29.

14.

Healthcare workers as parents: attitudes toward vaccinating their children against pandemic influenza A/H1N1.

Torun SD, Torun F, Catak B.

BMC Public Health. 2010 Oct 10;10:596. doi: 10.1186/1471-2458-10-596.

15.

The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study.

Rose MA, Damm O, Greiner W, Knuf M, Wutzler P, Liese JG, Krüger H, Wahn U, Schaberg T, Schwehm M, Kochmann TF, Eichner M.

BMC Infect Dis. 2014 Jan 22;14:40. doi: 10.1186/1471-2334-14-40.

16.

The Japanese experience with vaccinating schoolchildren against influenza.

Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M.

N Engl J Med. 2001 Mar 22;344(12):889-96.

17.

Vaccines for seasonal and pandemic influenza.

Nichol KL, Treanor JJ.

J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8.

PMID:
17163383
18.

Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.

Lugnér AK, van Boven M, de Vries R, Postma MJ, Wallinga J.

BMJ. 2012 Jul 12;345:e4445. doi: 10.1136/bmj.e4445.

19.

Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study.

Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J.

Lancet Infect Dis. 2012 Sep;12(9):696-702. doi: 10.1016/S1473-3099(12)70133-0. Epub 2012 Jun 26.

PMID:
22738894
20.

Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) cluster randomized trial: Pilot results from a household surveillance study to assess direct and indirect protection from influenza vaccination.

Kwong JC, Pereira JA, Quach S, Pellizzari R, Dusome E, Russell ML, Hamid JS, Feinberg Y, Winter AL, Gubbay JB, Sirtonski B, Moher D, Sider D, Finkelstein M, Loeb M; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Program Delivery and Evaluation Group.

Vaccine. 2015 Sep 11;33(38):4910-5. doi: 10.1016/j.vaccine.2015.07.044. Epub 2015 Jul 29.

Supplemental Content

Support Center